Michael D. Pak

Array ( [id] => 15713301 [patent_doc_number] => 20200103416 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => SNX9 as a novel biomarker for chronic inflammation and associated immunosuppresion and a new regulator of T cell receptor expression and function [patent_app_type] => utility [patent_app_number] => 16/501210 [patent_app_country] => US [patent_app_date] => 2019-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28946 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16501210 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17368343 [patent_doc_number] => 20220023395 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => METHODS OF TREATING OR PREVENTING CANCER WITH AN AGENT THAT DEPLETES TREGS AND A CHECKPOINT INHIBITOR [patent_app_type] => utility [patent_app_number] => 16/978949 [patent_app_country] => US [patent_app_date] => 2019-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26730 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16978949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16727848 [patent_doc_number] => 20210094995 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO CYTOKINES [patent_app_type] => utility [patent_app_number] => 15/733582 [patent_app_country] => US [patent_app_date] => 2019-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28257 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15733582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17407164 [patent_doc_number] => 11248033 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-15 [patent_title] => Methods and compositions for treating cancer [patent_app_type] => utility [patent_app_number] => 16/281472 [patent_app_country] => US [patent_app_date] => 2019-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 20 [patent_no_of_words] => 20008 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16281472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20373518 [patent_doc_number] => 12480950 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-25 [patent_title] => AKT-specific capture agents, compositions, and methods of using and making [patent_app_type] => utility [patent_app_number] => 16/280953 [patent_app_country] => US [patent_app_date] => 2019-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 66 [patent_no_of_words] => 20587 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16280953 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14685055 [patent_doc_number] => 20190241642 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => SYSTEM AND METHOD FOR HOMOGENOUS GPCR PHOSPHORYLATION AND IDENTIFICATION OF BETA-2 ADRENERGIC RECEPTOR POSITIVE ALLOSTERIC MODULATORS [patent_app_type] => utility [patent_app_number] => 16/269877 [patent_app_country] => US [patent_app_date] => 2019-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30534 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16269877 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14838887 [patent_doc_number] => 20190277844 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => DISRUPTION OF EGFR-SAR1 INTERACTION FOR CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 16/254287 [patent_app_country] => US [patent_app_date] => 2019-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15942 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16254287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14581357 [patent_doc_number] => 20190218287 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => TRPM4 CHANNEL INHIBITORS FOR STROKE TREATMENT [patent_app_type] => utility [patent_app_number] => 16/249706 [patent_app_country] => US [patent_app_date] => 2019-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13258 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16249706 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14535133 [patent_doc_number] => 20190203188 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => FUSION PROTEINS AND METHODS THEREOF [patent_app_type] => utility [patent_app_number] => 16/246167 [patent_app_country] => US [patent_app_date] => 2019-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41796 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16246167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14778067 [patent_doc_number] => 20190263931 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => ANTI-MCT1 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/240499 [patent_app_country] => US [patent_app_date] => 2019-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67605 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16240499 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14409797 [patent_doc_number] => 20190170742 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-06 [patent_title] => COMPOSITIONS, KITS AND METHODS FOR IN VITRO ANTIGEN PRESENTATION, ASSESSING VACCINE EFFICACY, AND ASSESSING IMMUNOTOXICITY OF BIOLOGICS AND DRUGS [patent_app_type] => utility [patent_app_number] => 16/228050 [patent_app_country] => US [patent_app_date] => 2018-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22170 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16228050 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19043604 [patent_doc_number] => 11932688 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-19 [patent_title] => Treatment for neoplastic diseases [patent_app_type] => utility [patent_app_number] => 16/228060 [patent_app_country] => US [patent_app_date] => 2018-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5135 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16228060 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16555772 [patent_doc_number] => 20210000920 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => INTRADUCTAL METHODS OF TREATMENT OF BREAST DISORDERS [patent_app_type] => utility [patent_app_number] => 16/956949 [patent_app_country] => US [patent_app_date] => 2018-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17087 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16956949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15117235 [patent_doc_number] => 20190345250 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-14 [patent_title] => ANTIBODY DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 16/226227 [patent_app_country] => US [patent_app_date] => 2018-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49194 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16226227 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14467839 [patent_doc_number] => 20190185562 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND LEPTIN RECEPTOR AND/OR GP130, AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/222800 [patent_app_country] => US [patent_app_date] => 2018-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28378 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16222800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14467859 [patent_doc_number] => 20190185572 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/209410 [patent_app_country] => US [patent_app_date] => 2018-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46138 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16209410 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14342275 [patent_doc_number] => 20190153110 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-23 [patent_title] => PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/201592 [patent_app_country] => US [patent_app_date] => 2018-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68519 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16201592 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14016529 [patent_doc_number] => 20190070258 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-07 [patent_title] => TARGETED OESOPHAGEAL ADMINISTRATION OF ZN-ALPHA2-GLYCOPROTEINS (ZAG), METHODS AND FORMULATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 16/192105 [patent_app_country] => US [patent_app_date] => 2018-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10676 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16192105 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19625137 [patent_doc_number] => 12163959 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-10 [patent_title] => Extracellular vesicle proteins and their use for cancer diagnosis, predicting response to therapy, and treatment [patent_app_type] => utility [patent_app_number] => 16/762440 [patent_app_country] => US [patent_app_date] => 2018-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 80 [patent_no_of_words] => 19799 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 137 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16762440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14655627 [patent_doc_number] => 20190234942 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => METHODS OF IDENTIFYING MODULATORS OF SAMTOR-GATOR1 INTERACTION AND USE OF SAME TO MODULATE mTORC1 [patent_app_type] => utility [patent_app_number] => 16/164644 [patent_app_country] => US [patent_app_date] => 2018-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19539 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16164644 [rel_patent_id] =>[rel_patent_doc_number] =>)